Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May 8;12(9):3348.
doi: 10.3390/jcm12093348.

Treat-to-Target in Systemic Lupus Erythematosus: Reality or Pipe Dream

Dina Zucchi  1   2 , Chiara Cardelli  1   2 , Elena Elefante  1 , Chiara Tani  1 , Marta Mosca  1
Affiliations
Review

Treat-to-Target in Systemic Lupus Erythematosus: Reality or Pipe Dream

Dina Zucchi et al. J Clin Med. .

Abstract

Treat-to-target is a therapeutic approach based on adjustments to treatment at set intervals in order to achieve well-defined, clinically relevant targets. This approach has been successfully applied to many chronic conditions, and in rheumatology promising results have emerged for rheumatoid arthritis. For systemic lupus erythematosus (SLE), defining the most meaningful treatment targets has been challenging, due to disease complexity and heterogeneity. Control of disease activity, the reduction of damage accrual and the patient's quality of life should be considered as the main targets in SLE, and several new drugs are emerging to achieve these targets. This review is focused on describing the target to achieve in SLE and the methods to do so, and it is also aimed at discussing if treat-to-target could be a promising approach also for this complex disease.

Keywords: low disease activity; quality of life; remission; systemic lupus erythematosus; treat-to-target; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Smolen J.S. Treat-to-target: Rationale and strategies. Clin. Exp. Rheumatol. 2012;30:S2–S6. - PubMed
    1. Solomon D.H., Bitton A., Katz J.N., Radner H., Brown E.M., Fraenkel L. Review: Treat to target in rheumatoid arthritis: Fact, fiction, or hypothesis? Arthritis Rheumatol. 2014;66:775–782. doi: 10.1002/art.38323. - DOI - PMC - PubMed
    1. Smolen J.S., Breedveld F.C., Burmester G.R., Bykerk V., Dougados M., Emery P., Kvien T.K., Navarro-Compan M.V., Oliver S., Schoels M., et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann. Rheum. Dis. 2016;75:3–15. doi: 10.1136/annrheumdis-2015-207524. - DOI - PMC - PubMed
    1. Smolen J.S., Landewe R.B.M., Bergstra S.A., Kerschbaumer A., Sepriano A., Aletaha D., Caporali R., Edwards C.J., Hyrich K.L., Pope J.E., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann. Rheum. Dis. 2023;82:3–18. doi: 10.1136/ard-2022-223356. - DOI - PubMed
    1. Mottonen T., Hannonen P., Leirisalo-Repo M., Nissila M., Kautiainen H., Korpela M., Laasonen L., Julkunen H., Luukkainen R., Vuori K., et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: A randomised trial. FIN-RACo trial group. Lancet. 1999;353:1568–1573. doi: 10.1016/S0140-6736(98)08513-4. - DOI - PubMed

LinkOut - more resources